RICHMOND — AstraZeneca has chosen Virginia as the site of its largest single manufacturing investment in company history, Governor Glenn Youngkin announced this week.
The global biopharmaceutical leader plans to build a state-of-the-art drug substance facility in the Commonwealth as part of its broader $50 billion U.S. investment strategy by 2030. Governor Youngkin was joined at the announcement by AstraZeneca CEO Pascal Soriot and White House National Economic Council Director Kevin Hassett.
“This project will set the standard for the latest technological advancements in pharmaceutical manufacturing,” Youngkin said. “It will create hundreds of highly skilled jobs and further strengthen the nation’s domestic supply chain.”
Soriot called the decision a reflection of Virginia’s workforce and life sciences ecosystem.
“It reflects the Commonwealth of Virginia’s desire to create highly skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines,” he said, adding that the investment will help AstraZeneca reach its goal of $80 billion in annual revenue by 2030.
The new facility will incorporate artificial intelligence, automation, and data analytics to support production in key therapeutic areas, including oncology, cardiovascular, renal, metabolism, respiratory, immunology, and rare diseases.
Virginia officials hailed the announcement as a major win for the state’s growing life sciences sector.
“This new partnership with AstraZeneca is an amazing opportunity for the Commonwealth,” said state Sen. Creigh Deeds. “It will transform our bioscience economy and reshore our critical pharmaceutical supply chain.”
AstraZeneca, headquartered in the United Kingdom, sells medicines in over 125 countries. The company focuses on developing treatments in oncology, rare diseases, cardiovascular, respiratory, renal, metabolism, and immunology.
Edited by Dan McDermott
